Erfan Bashar
Back to Intracerebral Haemorrhage

ICH Expansion and Reversal

~1 min read
Last medically reviewed:
On this pageTable of contents

Educational scope notice: This is a study note for medical students, not medical advice, diagnosis, or treatment guidance. Clinical management should follow local protocols and current guidelines.

The hematoma after intracerebral hemorrhage is not static. Expansion occurs early, most often within the first 2 hours, and predicts worse outcome. Everything in this note serves that clock: predict who expands, reverse what drives bleeding, and hold pressure steady.

Predicting expansion

Neuroimaging markers, together with time since onset and antithrombotic use, help predict expansion risk. The CTA spot sign is focal pooling of contrast within the hematoma, marking active extravasation. It significantly increases the likelihood of hematoma growth. About 30% of patients scanned within 6 hours of onset show it.

Reversing anticoagulation

Acute reversal pairs agent to anticoagulant. Prothrombin complex concentrate reverses warfarin-type vitamin K antagonists. Idarucizumab reverses the thrombin inhibitor dabigatran. Andexanet alfa reverses factor-Xa inhibitors such as rivaroxaban, apixaban, and edoxaban. Availability and cost vary by setting, so the pairing is the teaching point rather than any local protocol.

Blood pressure and what to avoid

Acute blood-pressure lowering after mild-to-moderate hemorrhage aims for smooth, sustained control with limited variability. That pattern appears to reduce expansion and improve outcome.

Prophylactic corticosteroids and continuous hyperosmolar therapy show no outcome benefit. Platelet transfusion outside emergency surgery or severe thrombocytopenia appears to worsen outcome.

For cerebellar hemorrhage, immediate evacuation with or without external ventricular drain now includes volume above 15 mL alongside deterioration, brainstem compression, and hydrocephalus.

Evidence anchors

Suggest a correction